Remove solutions irb-review
article thumbnail

WCG Revolutionizes Ethical Review Process with IRB+ Service, Achieving Unprecedented Efficiency Gains

WCG Clinical

PRINCETON, NJ, November 30, 2023 – WCG, the global leader in providing solutions that measurably improve and accelerate clinical research, announced today the official launch of IRB+, a groundbreaking service that transforms the landscape of Institutional Review Board (IRB) operations.

article thumbnail

WCG’s Unmatched Experience in Early Phase Hematology and Oncology

WCG Clinical

Unmatched Experience in Early Phase Hematology and Oncology Discover unparalleled expertise in phase I hematology and oncology study reviews with WCG. As the foremost leader in ethical and scientific review services for oncology studies in the US, we have successfully conducted over 3,300 early phase oncology study reviews.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Grand Rounds October 27, 2023: Digital, Decentralized and Democratized: Lessons From The Yale PaxLC Trial (Harlan M. Krumholz, MD, SM)

Rethinking Clinical Trials

PaxLC brings together many innovations including online screening, digital medical record review, e-consent, home-delivery of medications, local clinical blood draws, home-based biospecimen collection, online diaries and surveys, digital medical record outcomes, and participant-centricity, and return of results.

Trials 228
article thumbnail

WCG Raises the Bar in Quality Management Standards, Becoming ISO 9001 Certified in both IRB and IBC

WCG Clinical

PRINCETON, NJ, October 10, 2023: WCG, the global leader in providing solutions that measurably improve and accelerate clinical research, announced today the extension of its ISO 9001 certification to its Institutional Biosafety Committee (IBC) services by BSI. For more information, visit [link].

article thumbnail

Unpacking IRB Innovations for Decentralized Clinical Trials

Advarra

Ethical oversight committees (like Advarra’s institutional review board [IRB]) continue to innovate to keep pace with the rapid changes and evolution of research conduct. It’s also important for IRBs to understand how their review requirements can impact overall study efficiencies. What is this innovation?

article thumbnail

?5 Things You Need to Know from Our Recent Gene Therapy Webinar

Worldwide Clinical Trials

Fewer staff creates many problems, including less bandwidth to meet for reviews and approvals. Patients often don’t have time to wait for delays to resolve, so if the Institutional Review Board (IRB) is unable to meet to approve their participation, then patients may have to move on to seek other more available treatments.

article thumbnail

Patient Retention Insights: Use Payments to Enrich Diversity, DCTs Need Special Attention

ACRP blog

A key focus in the clinical trial diversity plans that are part of this year’s omnibus spending bill signed by President Biden should be participant payments and reimbursement, writes Kelly FitzGerald, PhD, IRB Executive Chair and Vice President for IBC Affairs at WCG IRB. There are no simple solutions.